Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial

Keyphrases

• Confidence Interval 100%
• Hazard Ratio 100%
• Acute Coronary Event 100%
• Body Mass 100%
• Acute Coronary Syndrome 100%
• P2Y12 Inhibitors 100%
• Overweight Patient 83%
• Myocardial Infarction 50%
• Cardiovascular Mortality 50%
• Prasugrel 50%
• Non-weight Bearing 50%
• Net Clinical Benefit 50%
• Ischemic Events 50%
• Bleeding 33%
• Bleeding Risk 33%
• Clopidogrel 33%
• Bleeding Academic Research Consortium 33%
• Platelet Function Tests 33%
• Body Mass Index 16%
• Percutaneous Coronary Intervention 16%
• Statistical Significance 16%
• Clinical Benefit 16%
• Platelet Function 16%
• Clinical Practice Guidelines 16%
• Event Rate 16%
• Relative Reduction 16%
• Non-inferiority 16%
• Bleeding Events 16%
• Dual Antiplatelet Therapy 16%
• De-escalation Therapy 16%
• Antiplatelet Strategy 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Obesity 100%
• Acute Coronary Syndrome 100%
• Heart Infarction 30%
• Prasugrel 30%
• Clopidogrel 20%
• Antiplatelet 20%